Predicting injection site muscle damage. III: Evaluation of intramuscular formulations in the L6 cell model.
Evans
L A
LA
Pharmaceutical R & D Department, Pfizer, Inc., Groton, Connecticut 06340, USA.
Genereux
P E
PE
Gibbs
E M
EM
Sutton
S C
SC
D000818:Animals; D000890:Anti-Infective Agents; D017963:Azithromycin / Q000008:administration & dosage / Q000633:toxicity; D002478:Cells, Cultured; D002626:Chemistry, Pharmaceutical; D003402:Creatine Kinase / Q000378:metabolism; D004077:Digoxin / Q000008:administration & dosage / Q000633:toxicity; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D024841:Fluoroquinolones; D007273:Injections, Intramuscular / Q000009:adverse effects*; D018482:Muscle, Skeletal / Q000166:cytology / Q000201:enzymology / Q000293:injuries*; D011237:Predictive Value of Tests; D015363:Quinolones / Q000008:administration & dosage / Q000633:toxicity; D011817:Rabbits; D051381:Rats
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C068581:danofloxacin; D004077:Digoxin; D017963:Azithromycin; D003402:Creatine Kinase